Yunjiang Zhou

State Key Laboratory Of Natural Medicines
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models.

Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models.

Journal: Journal of medicinal chemistry

Published: April 23, 2026

Discovery of the First Highly Potent and Selective Peptide Inhibitor Targeting Microtubule-MAP7 Interaction via Structure-Based Design for Suppressing Colorectal Cancer Cell Proliferation.

Discovery of the First Highly Potent and Selective Peptide Inhibitor Targeting Microtubule-MAP7 Interaction via Structure-Based Design for Suppressing Colorectal Cancer Cell Proliferation.

Journal: Journal of medicinal chemistry

Published: January 21, 2026

DPP9 regulates NQO1 and ROS to promote resistance to chemotherapy in liver cancer cells.

DPP9 regulates NQO1 and ROS to promote resistance to chemotherapy in liver cancer cells.

Journal: Redox biology

Published: May 13, 2024

The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis.

The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis.

Journal: Molecular cancer

Published: November 15, 2023

Serotonin Receptor HTR2B Facilitates Colorectal Cancer Metastasis via CREB1-ZEB1 Axis-Mediated Epithelial-Mesenchymal Transition.

Serotonin Receptor HTR2B Facilitates Colorectal Cancer Metastasis via CREB1-ZEB1 Axis-Mediated Epithelial-Mesenchymal Transition.

Journal: Molecular cancer research : MCR

Published: June 27, 2023

FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway.

FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway.

Journal: The Journal of clinical investigation

Published: January 24, 2022

A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy.

A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy.

Journal: Frontiers in pharmacology

Published: November 09, 2021

A Supramolecular Nanomedicine Based on Bendamustine and MDM2-Targeted D-peptide Inhibitor for Breast Cancer Therapy.

A Supramolecular Nanomedicine Based on Bendamustine and MDM2-Targeted D-peptide Inhibitor for Breast Cancer Therapy.

Journal: Advanced healthcare materials

Published: May 20, 2021

Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation.

Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation.

Journal: Cancer immunology research

Published: December 21, 2020

An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy.

An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy.

Journal: Advanced healthcare materials

Published: December 15, 2020

ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1.

ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1.

Journal: Cancers

Published: November 12, 2019

Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.

Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.

Journal: Molecules (Basel, Switzerland)

Published: October 26, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026